Search

Siltuximab

Siltuximab prevents the binding of IL-6 to soluble and membrane-bound IL-6 receptors by forming high affinity complexes with human interleukin-6 (IL-6). … MCD is a rare blood disorder caused by dysregulated IL-6 production, proliferation of lymphocytes, and subsequent enlargement of the lymph nodes.

Miconazole

[L14021, L14024, L14027, L14033, L14396] Miconazole is thought to act primarily through the inhibition of fungal CYP450 14α-lanosterol demethylase activity. … [A214523, L14021] It is currently available as a variety of prescription and over the counter products.

Lithium citrate

Human immunoglobulin G

IVIg contains the same distribution of IgG antibody subclasses as is found in the general human population. … IVIg is used in the treatment of immunodeficiencies, as well as autoimmune and inflammatory disorders.

Grapiprant

These molecules were derived from acylsulfonamide and are characterized to be a novel series of para-N-acylaminomethylbenzoic acid known to be prostaglandin receptor antagonists. … Grapiprant, also known as AT-001 and CJ-023, is a drug from the piprant class.

Tolrestat

It was sold under the tradename Alredase but was discontinued by Wyeth in 1997 because of the risk of severe liver toxicity and death. … While it was approved for marketed in several countries, it failed a Phase III trial in the U.S. due to toxicity and never received FDA approval.

Lovotibeglogene autotemcel

12 years and older to be approved by the FDA. … [A262736,L49256] On December 8, 2023, lovotibeglogene autotemcel was approved by the FDA under the brand name Lyfgenia for the treatment of sickle cell disease (SCD) in patients ages 12 and older who

Deferasirox

Deferasirox is an iron chelator and the first oral medication FDA approved for chronic iron overload in patients receiving long term blood transfusions.

Ethanolamine oleate

It is composed of ethanolamine, a basic substance, which when combined with oleic acid forms a clear, straw to pale yellow colored, deliquescent oleate.

Tarlatamab

T-cell engager to receive marketing approval. … Tarlatamab is a first-in-class T-cell engager used to treat extensive-stage small cell lung cancer.